US — Ars Technica
GLP-1 drugs could have a surprisingly large environmental payoff
Policy1 min read
A new study suggests that GLP-1 weight-loss medicines, such as Ozempic and Wegovy, could change more than people's bodies. If many people used them, they could reshape the global food system and free up farmland.
What the study found
Researchers used a large computer simulation to test what might happen if GLP-1 drugs were used in different ways. These drugs reduce appetite, so people eat fewer calories. When people eat less, food producers make less food, which changes prices, trade, and how much land is farmed.
Key numbers
- Reduced calorie intake could prevent up to 6.6 million deaths each year by 2050, if the drugs are widely used by adults with obesity.
- Up to 32 million hectares of farmland could be freed up. That is a bit more than the size of Italy.
- When fewer calories were combined with healthier diets, up to 7 million deaths could be avoided each year by 2050.
- In that combined case, about 46 million hectares of farmland could be freed up for other uses.
Why food is connected
Food systems cross borders. If people in one part of the world buy less food, farms, trade, and prices can change in other places too. This means people who never take the drugs can still be affected.
Why it matters
The food system may respond in surprising ways. Cheaper food could lead non-users to eat more, which cancels out some benefits. The researchers say the results should not be read as a reason to give more people weight-loss medicine. Healthier food also needs to be easier to get, cheaper, and more appealing.
Glossary
- GLP-1
- A type of medicine that lowers appetite, so people eat less. Ozempic and Wegovy are examples.
- Ozempic
- A brand-name GLP-1 medicine that is used to treat diabetes and has also been used for weight loss.
- Wegovy
- A brand-name GLP-1 medicine approved for weight loss.